Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis

NCT03044353 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03044353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03044353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
July 10, 2017
Completion date
January 3, 2019
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis